Intellectual Property
Our patented technology for carbohydrate attachment is wholly owned by Design-Zyme LLC. We are actively pursuing intellectual property protection of our discoveries and products. The company has multiple allowed US patents and is aggressively seeking patent protection from the USPTO and PCT for our broad range of discoveries. Design-Zyme maintains in-house patent counsel to oversee maintenance and prosecution of its patent estate.
Issued Patents
In Vitro Glycosylation of Proteins and Enzymes - The present invention comprises a glycosylated protein wherein the starting protein has an amino sidechain with a nucleophilic moiety which reacts with a carbohydrate having an oxazoline moiety on the reducing end to covalently bond the amino sidechain of the starting protein with the oxazoline moiety. The glycosylated protein substantially retains the structure and function of the starting protein.
In Vitro Glycosylation of Proteins and Enzymes - The present invention is broadly concerned with new in vitro glycosylation methods that provide rational approaches for producing glycosylated proteins, and the use of glycosylated proteins. In more detail, the present invention comprises methods of glycosylating a starting protein having an amino sidechain with a nucleophilic moiety, comprising the step of reacting the protein with a carbohydrate having an oxazoline moiety on the reducing end thereof, to covalently bond the amino sidechain of the starting protein with the oxazoline moiety, wherein the glycosylated protein substantially retains the structure and function of the starting protein. Target proteins include oxidase, oxidoreductase and dehydrogenase enzymes. The glycosylated proteins advantageously have molecular weights of at least ∼7500 Da. In a further embodiment, the present invention concerns the use of glycosylated proteins, fabricated by the methods disclosed herein, in the assembly of amperometric biosensors.
In Vitro Glycosylation of Proteins and Enzymes - The present invention comprises methods of glycosylating a starting protein having an amino sidechain with a nucleophilic moiety, comprising the step of reacting the protein with a carbohydrate having an oxazoline moiety on the reducing end thereof, to covalently bond the amino sidechain of the starting protein with the oxazoline moiety. The glycosylated protein substantially retains the structure and function of the starting protein. This is the parent application for the in vitro glycosylation platform.
Published Patent Applications - Pending
U.S. Pat. Appl. 18/196,214
Universal Adjuvant for Nasal, Oral, and Intramuscular Delivery of Vaccines - The present invention is broadly concerned with a vaccine composition comprising at least one immunogen modified by in vitro glycosylation methods. In particular, this method generates glycosylated versions of immunogens via the reducing end of a linear carbohydrate with a reducing end containing an N-acyl-2-amino moiety. This invention allows for the custom control of placement and amounts of a linear carbohydrate on the immunogen. The immunogen may be singular or attached to a nanoparticle. The glycosylated immunogen of the vaccine composition may be self-adjuvanting for enteral, parenteral, topical, intravaginal, and intranasal delivery.
PCT Appl. No. PCT/US23/
23550
Universal Adjuvant for Nasal, Oral, and Intramuscular Delivery of Vaccines - The present invention is broadly concerned with a vaccine composition comprising at least one immunogen modified by in vitro glycosylation methods. In particular, this method generates glycosylated versions of immunogens via the reducing end of a linear carbohydrate with a reducing end containing an N-acyl-2-amino moiety. This invention allows for the custom control of placement and amounts of a linear carbohydrate on the immunogen. The immunogen may be singular or attached to a nanoparticle. The glycosylated immunogen of the vaccine composition may be self-adjuvanting for enteral, parenteral, topical, intravaginal, and intranasal delivery.
U.S. Pat. Appl. 18/499,765
Self-Adjuvanting Multi-Protein Complexes for Modular Vaccine Production - The present invention is broadly concerned with a vaccine composition comprising a central carrier, at least one linear carbohydrate molecule, and at least one immunogen molecule, wherein each of the at least one linear carbohydrate molecule and at least one immunogen molecule are covalently bound to the carrier via respective covalent linkages. Vaccine compositions comprising multivalent carriers and related methods may find various therapeutic and prophylactic applications for inducing an immune response against, treating, or preventing a bacterial, viral, fungal, or protozoan infection, including, but are not limited to, coronaviruses, Lyme Disease, Chlamydia, and the related diseases thereof.
PCT Appl. No. PCT/US23/
78438
Self-Adjuvanting Multi-Protein Complexes for Modular Vaccine Production - The present invention is broadly concerned with a vaccine composition comprising a central carrier, at least one linear carbohydrate molecule, and at least one immunogen molecule, wherein each of the at least one linear carbohydrate molecule and at least one immunogen molecule are covalently bound to the carrier via respective covalent linkages. Vaccine compositions comprising multivalent carriers and related methods may find various therapeutic and prophylactic applications for inducing an immune response against, treating, or preventing a bacterial, viral, fungal, or protozoan infection, including, but are not limited to, coronaviruses, Lyme Disease, Chlamydia, and the related diseases thereof.
U.S. Pat. Appl. 19/256,289
A Vaccine Composition for Lyme Disease - The present invention is broadly concerned with a vaccine compositions comprising a plurality of immunogens attached to a carrier for inducing an immune response against a pathogen selected from the Anaplasma, Babesia, Borrelia, and Chlamydia genera. Vaccine compositions comprising multivalent carriers and related methods using the vaccine compositions in various therapeutic and prophylactic applications for inducing an immune response against, treating, or preventing an infection caused by the Anaplasma, Babesia, Borrelia, or Chlamydia pathogens, and the related diseases thereof.
Patent Applications Pending
USPTO No. 63/839,174
A novel nitazene hapten for vaccine development against nitazene opioids
USPTO No. 63/839,178
A novel xylazine hapten for vaccines against xylazine exposure
USPTO No. 63/839,180
A novel nitazene hapten for vaccine development against nitazene opioids
USPTO No. 63/839,182
A novel nitazene hapten for vaccine development against nitazene opioids
USPTO No. 63/839,184
A novel nitazene hapten for vaccine development against fentanyl opioids
USPTO No. 63/839,189
A novel poly-hapten vaccine for opioid use disorder
Jointly Developed With and IP Owned by Cal Tech
Axel Scherer, Taeyoon Jeon, Changsoon Choi, Peter A Petillo, Jack Jewell, and John Richard Ordonez-Varela
ABSTRACT: A leak-detection system comprises networked imaging packages including an infrared camera based on microbolometer arrays, one or more filters, and a processor. The processor uses one or more novel processing methods for identifying gas leakages in a monitored facility. In some embodiments, the imaging packages are installed at various locations in the monitored facility. In some other embodiments, the leak-detection system is embodied as a mobile platform, wherein the networked imaging packages are coupled to drones that fly throughout the monitored facility to monitor for gas leakages. The flight path of the cameras may be pre-programmed and may further be alterable in real time. The novel processing technique(s) employed by the leak-detection system disclosed herein involve the use of multiple unique filters that facilitate enhancing the signal-to-noise ratio of captured images; that is, enhancing the contrast of a monitored gas against other objects. The novel processing techniques include one or more of the following: (i) two-image subtraction; (ii) time-resolved imaging; and (iii) multi-filter detection. Additionally, in some embodiments, the imaging packages include a visible (light) camera in addition to an IR camera.
Axel Scherer, Peter A Petillo, Samson Chen, and Azita Emami
ABSTRACT: A smart cage includes radiofrequency transceivers and tags attached to laboratory animals. The tags include sensors to detect monitorable conditions of the laboratory animals. The sensors include working electrodes, counter electrodes, reference electrodes, and potentiostats. The top surface of the electrodes is coated with ionophores or enzymes which detect the monitorable conditions of the laboratory animals.
Samson Chen, Axel Scherer, Dvin I. Adalian, Peter Petillo, Muhammad Musab Jilani, Xiomara L. Madero, and Deepan Kishore Kumar
ABSTRACT: A sensor implanted in tissues and including a sensing layer is fabricated by mixing the signal transduction enzyme with non-reactive components including buffer salts and fillers, and spin coating the enzyme onto a substrate. The signal transduction enzyme is crosslinked by introducing the coated substrate in a vacuum chamber. In the chamber, a crosslinker evaporates and is deposited onto the enzyme, therefore crosslinking the enzyme.
Axel A. Scherer, and Peter A. Petillo
ABSTRACT: A multilayer structure can selectively bind certain molecules, due to reentrant spaces having an appropriate size. The multilayers can be fabricated by alternating layers of two different materials having different etching rate. The layers of the material having a higher etching rate form reentrant spaces which can protect molecules from further chemical interactions.